B6JOlaHsd.Cg-Tg(KRT14-FLT4/IGHG1)#Ali/Oulu
| Status | Available to order |
| EMMA ID | EM:10725 |
| Citation information | RRID:IMSR_EM:10725 Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information. |
| International strain name | B6JOlaHsd.Cg-Tg(KRT14-FLT4/IGHG1)#Ali/Oulu |
| Alternative name | K14-VEGFR3-Ig |
| Strain type | Transgenic Strains |
| Allele/Transgene symbol | Tg(KRT14-FLT4/IGHG1)#Ali |
| Gene/Transgene symbol | Tg(KRT14-FLT4/IGHG1)#Ali |
Information from provider
| Provider | Kari Alitalo |
| Provider affiliation | Translational Cancer Biology Research Program; Institute of Biomedicine, University of Helsinki |
| Genetic information | FLT4/IGHG1 (VEGFR3-Ig) is expressed in the skin under the control of the K14 promoter. |
| Phenotypic information | Homozygous:Transgenic mice, only one allele required for the phenotype.Heterozygous:Dermal lymphatic vessels are lacking. Edema in the paws. |
| References |
|
| Homozygous fertile | yes |
| Homozygous viable | yes |
| Homozygous matings required | no |
| Immunocompromised | no |
Information from EMMA
| Archiving centre | University of Oulu, Oulu, Finland |
Literature references
- Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3.;Mäkinen T, Jussila L, Veikkola T, Karpanen T, Kettunen M I, Pulkkanen K J, Kauppinen R, Jackson D G, Kubo H, Nishikawa S, Ylä-Herttuala S, Alitalo K, ;2001;Nature medicine;7;199-205; 11175851